A. OBJECTIVES AND GOALS. The development and application of biomarkers in neurodegenerative diseases has become increasingly important to clinical practice, epidemiology and therapeutic trials. While substantial progress has been made at the basic science level in understanding the pathophysiology and development of animal models of HIV-D, there are significant limitations in our current ability to predict disease onset, to give definitive diagnoses, to measure disease progression and to detect accurately the effects of therapeutic intervention. Thus the development of objective biomarkers is critical to further our progress in this field. Realizing the potential importance of biomarkers, the Food and Drug Administration is making a major effort to bring biomarkers into the mainstream of drug discovery (1). The objectives of the Core are: 1. To assist in the development and monitoring of surrogate markers for HIV-D. 2. To provide mentorship and consultation for Neuro-AIDS researchers in the development of clinically useful surrogate markers for HIV-D and to validate these as associative, predictive markers, and as longitudinal markers of therapeutic effectiveness. This Core will interact extensively with the Clinical Outcomes Core (using the characterized samples derived from that Core), the Education and Skills Development Core (to disseminate information about the newly developed surrogate markers, and to assist with skill development in their application), and with the Therapeutics Core (to validate these markers in animal models). The statistical resources of the Clinical Outcomes Core will be essential for the interpretation of the clinical utility of markers derived from this core. Further details of the interactions are provided in individual Cores, and the overall Outline. This Core will provide a valuable resource to JHU investigators, and to the global Neuro-AIDS community. There is no similar systematic attempt to develop a series of clinically useful surrogate markers, so this Core will have a major impact on the field.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Center Core Grants (P30)
Project #
3P30MH075673-03S2
Application #
7714476
Study Section
Special Emphasis Panel (ZMH1)
Project Start
Project End
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
3
Fiscal Year
2008
Total Cost
$322,298
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Rojas, Camilo; Stathis, Marigo; Coughlin, Jennifer M et al. (2018) The Low-Affinity Binding of Second Generation Radiotracers Targeting TSPO is Associated with a Unique Allosteric Binding Site. J Neuroimmune Pharmacol 13:1-5
Chan, Parco; Saleem, Mahwesh; Herrmann, Nathan et al. (2018) Ceramide Accumulation Is Associated with Declining Verbal Memory in Coronary Artery Disease Patients: An Observational Study. J Alzheimers Dis 64:1235-1246
Mohamed, M; Barker, P B; Skolasky, R L et al. (2018) 7T Brain MRS in HIV Infection: Correlation with Cognitive Impairment and Performance on Neuropsychological Tests. AJNR Am J Neuroradiol 39:704-712
Sacktor, Ned; Skolasky, Richard L; Moxley, Richard et al. (2018) Paroxetine and fluconazole therapy for HIV-associated neurocognitive impairment: results from a double-blind, placebo-controlled trial. J Neurovirol 24:16-27
Barinka, Cyril; Novakova, Zora; Hin, Niyada et al. (2018) Structural and computational basis for potent inhibition of glutamate carboxypeptidase II by carbamate-based inhibitors. Bioorg Med Chem :
Lemberg, Kathryn M; Vornov, James J; Rais, Rana et al. (2018) We're Not ""DON"" Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine. Mol Cancer Ther 17:1824-1832
Capó-Vélez, Coral M; Delgado-Vélez, Manuel; Báez-Pagán, Carlos A et al. (2018) Nicotinic Acetylcholine Receptors in HIV: Possible Roles During HAND and Inflammation. Cell Mol Neurobiol :
Nedelcovych, Michael T; Gadiano, Alexandra J; Wu, Ying et al. (2018) Pharmacokinetics of Intranasal versus Subcutaneous Insulin in the Mouse. ACS Chem Neurosci 9:809-816
Sacktor, Ned (2018) Changing clinical phenotypes of HIV-associated neurocognitive disorders. J Neurovirol 24:141-145
Capó-Vélez, Coral M; Morales-Vargas, Bryan; García-González, Aurian et al. (2018) The alpha7-nicotinic receptor contributes to gp120-induced neurotoxicity: implications in HIV-associated neurocognitive disorders. Sci Rep 8:1829

Showing the most recent 10 out of 164 publications